Accustem Sciences Inc. (ACUT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in USD.

Revenue Quarterly

0 35K 70K 105K Q2 '26: 98.4K Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-1.2M -800K -400K 0 400K 800K 1.2M Q3 '21: -62.7K Q4 '21: -543.5K Q1 '22: -790.5K Q2 '22: -1.1M Q3 '22: -899.1K Q4 '22: -978.5K Q1 '23: -833.3K Q2 '23: -372.8K Q3 '23: -598.5K Q4 '23: -246K Q1 '24: -526.6K Q2 '24: -278.2K Q3 '24: -328.2K Q4 '24: -372.1K Q1 '25: -440.4K Q2 '25: -401.4K Q3 '25: -399.9K Q4 '25: -514.4K Q1 '26: -485.9K Q2 '26: -252.6K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-1.2M -800K -400K 0 400K 800K 1.2M Q3 '21: -62.7K Q4 '21: -543.5K Q1 '22: -790.5K Q2 '22: -1.1M Q3 '22: -899.1K Q4 '22: -978.5K Q1 '23: -833.3K Q2 '23: -372.8K Q3 '23: -598.5K Q4 '23: -246K Q1 '24: -526.6K Q2 '24: -278.2K Q3 '24: -328.2K Q4 '24: -372.1K Q1 '25: -440.4K Q2 '25: -401.4K Q3 '25: -399.9K Q4 '25: -514.4K Q1 '26: -485.9K Q2 '26: -252.6K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q1 '22: 372K Q2 '22: -1M Q3 '22: -555.3K Q4 '22: -622.3K Q1 '23: -446.1K Q2 '23: -522.9K Q3 '23: -351.6K Q4 '23: -295K Q1 '24: -237.4K Q2 '24: -209.2K Q3 '24: -217.9K Q4 '24: 414 Q1 '25: -290.2K Q2 '25: 21.6K Q3 '25: -604.1K Q4 '25: 22.4K Q1 '26: -374.2K Q2 '26: -248.8K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-1.1M -700K -350K 0 350K 700K 1.1M Q1 '22: 363.8K Q2 '22: -1M Q3 '22: -555.3K Q4 '22: -622.3K Q1 '22 Q2 '22 Q3 '22 Q4 '22

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 6M 12M 18M Q1 '21: 10M Q2 '21: 10M Q3 '21: 10M Q1 '22: 10M Q2 '22: 11.3M Q3 '22: 11.3M Q1 '23: 11.3M Q2 '23: 11.3M Q3 '23: 11.3M Q1 '24: 11.3M Q2 '24: 11.3M Q3 '24: 11.3M Q1 '25: 12.7M Q2 '25: 16.1M Q3 '25: 16.1M Q1 '26: 16.1M Q2 '26: 16.1M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.45 -0.30 -0.15 0.00 0.15 0.30 0.45 Q4 '21: -0.08 Q1 '22: -0.16 Q2 '22: -0.25 Q3 '22: -0.32 Q4 '22: -0.35 Q1 '23: -0.34 Q2 '23: -0.27 Q3 '23: -0.24 Q4 '23: -0.17 Q1 '24: -0.15 Q2 '24: -0.14 Q3 '24: -0.12 Q4 '24: -0.13 Q1 '25: -0.11 Q2 '25: -0.11 Q3 '25: -0.10 Q4 '25: -0.11 Q1 '26: -0.11 Q2 '26: -0.11 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.